Breaking News From Pharma & Bio Ingredients
Par Gets OK for Generic Cefprozil
Posted on 2005-12-30 15:22:00
Par Pharmaceutical Companies, Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for cefprozil for oral suspension. Cefprozil is the generic version of Bristol-Myers Squibb Company's broad-spectrum cephalosporin antibiotic Cefzil. Annual U.S. sales of Cefzil® for Oral Suspension exceed $100 million.
Par will begin shipping the product immediately. Cefprozil for oral suspension is available in strengths of 125 mg/5 mL and 250 mg/5 mL.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. In 2005, Par received approval for and introduced Megace® ES, its first branded pharmaceutical product, and expects to launch its second in 2006. Par's Generic Products Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. Par manufactures, markets or licenses more than 90 generic drugs. For press release and other company information, visit http://
Subscribe via RSS
